EU IP Law Reform Won’t Protect Pharma’s Commercially Confidential Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug companies arguing that reform of EU intellectual property law would help them to protect commercially sensitive clinical trial information may be wasting their time.